Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Dsi2.0

DSIP – Forschung

Überwiegend Mechanismus / Beobachtung

12 begutachtete Studien

Was die Evidenz sagt

Überwiegend Mechanismus / Beobachtung

Die meisten Studien zu DSIP sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.

Die meiste Evidenz stammt aus gemischt-qualitativen randomisierten Studien, veröffentlicht 1984–2011 mit einer typischen Studiengröße von 14 Teilnehmenden.

Basierend auf 12 Studien · 6 RCTs · 14 Teilnehmende insgesamt

Konfidenz

Mittlere Konfidenz

Nach Outcome

Sleep & insomniaDelta-Schlaf-induzierendes Peptid, untersucht für den Schlaf bei schwerer Insomnie; nur kleine, alte, uneindeutige Humandaten und unbekannte langfristige/moderne Sicherheit. · Nicht etabliert
Überwiegend Mechanismus / Beobachtung8 Studien
Anxiety & stressPostulierte stressprotektive/adaptive Wirkung (präklinisch) mit reduzierten chronischen Schmerz- und depressiven Zuständen in einer offenen Pilotstudie; Evidenz von niedriger Qualität. · Nicht etabliert
Zu wenige bewertete Studien2 Studien
Pain & analgesia
Zu wenige bewertete Studien1 Studie

Ältere Forschungsbasis

Neueste Studie von 2011

198419972011

1RCT2009

Pomfrett CJ, Dolling S, Anders NR, Glover DG, Bryan A, Pollard BJ · Eur J Anaesthesiol (2009)

Quelle ansehen

2RCT1989

Bjartell A, Ekman R, Bergquist S, Widerlöv E · Psychoneuroendocrinology (1989)

Quelle ansehen

3RCT1992

Bes F, Hofman W, Schuur J, Van Boxtel C · Neuropsychobiology (1992)

Quelle ansehen

4RCT1994

Chiodera P, Volpi R, Capretti L, Giacalone G, Caffarri G, Davoli C · Horm Res (1994)

Quelle ansehen

5Beobachtungsstudie1992

Einfach gesagt: CSF DSIP-LI was significantly correlated with polysomnography the night before the LP: with stage 3 sleep... Whether this first report of a potential relationship between CSF DSIP-LI and slow-wave sleep in man might be generalized to sleep in nonpsychiatric subjects awaits further study.

van Kammen DP, Widerlöv E, Neylan TC, Ekman R, Kelley ME, Mouton A, et al. · Sleep (1992)

Measured cerebrospinal-fluid DSIP-like immunoreactivity (DSIP-LI) and polysomnography in 15 drug-free male schizophrenic volunteers
Endogenous CSF DSIP-LI correlated with stage 3 / delta slow-wave sleep measures the night before lumbar puncture
This is a correlational study of endogenous DSIP — it did not administer exogenous DSIP

Quelle ansehen

6RCTn=14 · very small study1987

Einfach gesagt: DSIP was administered under placebo-controlled, double-blind conditions for 7 successive nights... The treatment substantially improved night sleep with the first and additionally with repeated doses... The study demonstrates the efficacy of DSIP for the treatment of impaired sleep and daytime functions as well.

Schneider-Helmert D. · Eur Neurol (1987)

Placebo-controlled, double-blind study of intermediate-term DSIP over 7 successive nights in 14 middle-aged chronic insomniacs
Reported that DSIP substantially improved night sleep (acutely and with repeated doses) and that sleep efficiency and daytime alertness/performance reached normal-control levels
Single author (Schneider-Helmert) — the same investigator behind most of the positive 1980s DSIP sleep claims

Quelle ansehen

7Tierstudie2009

Einfach gesagt: Last 10% (most aged) of mice which received Deltaran lived for 16% longer than the controls... Also Deltaran slowed the spontaneous carcinogenesis parameters.

Voĭtenkov VB, Popovich IG, Zabezhinskiĭ MA, Iurova MA, Piskunova TA, Mikhaleva II. · Adv Gerontol (2009)

Female SHR mice received monthly 5-day subcutaneous courses of the DSIP preparation 'Deltaran' across their lifespan
The most-aged 10% of treated mice lived ~16% longer than controls, with higher locomotor and exploratory activity
Treated mice showed anxiolytic-type behaviour (more time in open arms of the elevated plus maze) and slowed spontaneous carcinogenesis

8RCT1987

Einfach gesagt: For NREM sleep time and stage 2 sleep differences between DSIP and a placebo were significant, but the same differences existed already for the baseline values. It can be concluded that sleep improvement under DSIP treatment is of little clinical significance.

Monti JM, Debellis J, Alterwain P, Pellejero T, Monti D. · Int J Clin Pharmacol Res (1987)

Double-blind, placebo-controlled crossover polysomnography trial of IV DSIP (25 nmol/kg) over four nights in insomniac patients, by an independent (Uruguayan) group
Some sleep parameters (awakenings, NREM latency, waking time) decreased under DSIP, but differences from placebo were not clearly attributable to the peptide — the same differences already existed at baseline
Slow-wave sleep (stages 3 and 4) and REM were not modified

9Tierstudie2011

Einfach gesagt: Subcutaneous injection to the rats... with 10 microg/100 g body weight of delta-sleep inducing peptide (DSIP) suppresses lipid peroxidation preventing the increasing of malonic dialdehyde level in rats tissues and plasma, possesses a powerful antioxidant effect.

Bondarenko TI, Maĭboroda EA, Mikhaleva II, Prudchenko IA. · Adv Gerontol (2011)

Rat study of DSIP's proposed geroprotective/antioxidant mechanism across ages 2-24 months
Subcutaneous DSIP suppressed lipid peroxidation and lowered malondialdehyde in tissues and plasma
Stimulated endogenous antioxidant defences — superoxide dismutase, catalase, and ceruloplasmin activities, plus non-enzymatic antioxidants

10Übersicht1984

Einfach gesagt: Two different studies showed improvement of sleep following single injections of 25 nmol/kg b.w. before sleep. Repeated administrations indicated a buildup with normalization of sleep structure after four administrations.

Schneider-Helmert D. · Eur Neurol (1984)

Summary of early human investigations of DSIP injections in insomnia
Reported improved sleep after single 25 nmol/kg subcutaneous injections before sleep, with normalization of sleep structure after repeated administration
Morning injections still improved night sleep, while two daily doses did not — pointing to a complex, non-dose-linear effect

Quelle ansehen

11Open-Label1984

Einfach gesagt: DSIP lowered significantly the pain levels of 6 out of 7 patients after intravenous administration on 5 consecutive days followed by 5 injections every 48-72 h. Remarkably, a simultaneous significant reduction of the concomitantly occurring depressive states was observed.

Larbig W, Gerber WD, Kluck M, Schoenenberger GA. · Eur Neurol (1984)

Open clinical pilot of 7 patients with chronic pain (migraine, vasomotor headache, chronic tinnitus, psychogenic pain attacks)
Intravenous DSIP significantly lowered pain levels in 6 of 7 patients, with baseline-versus-follow-up comparison
A simultaneous significant reduction in concomitant depressive states was reported

Quelle ansehen

12Open-Label1984

Einfach gesagt: In an open study 7 patients with severe insomnia were treated by a series of 10 injections with the delta-sleep-inducing peptide (DSIP). In all but 1 case sleep was normalized for follow-up periods of 3-7 months.

Kaeser HE. · Eur Neurol (1984)

Open (uncontrolled) study of 7 patients with severe insomnia given a series of 10 DSIP injections
Sleep was reported normalized in all but 1 patient, with follow-up of 3-7 months, and daytime mood/performance improved
Tiny, open-label, 1984 study with no placebo control — hypothesis-generating only

Quelle ansehen

In der Forschungsbibliothek ansehen

DSIP – Forschung

Überwiegend Mechanismus / Beobachtung

Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia.

Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man.

Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.

Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men.

Delta sleep-inducing-peptide-like immunoreactivity (DSIP-LI) and delta sleep in schizophrenic volunteers.

Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.

Effect of delta-sleep inducing peptide preparation Deltaran on longevity, physiological functions, and carcinogenesis in mice.

Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.

Mechanism of delta-sleep inducing peptide geroprotective activity.

DSIP in insomnia.

Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study.

A clinical trial with DSIP.